|
Report Date : |
19.01.2013 |
IDENTIFICATION DETAILS
|
Name : |
SAMU MEDIAN CO., LTD. |
|
|
|
|
Registered Office : |
254-15, Dugok-ri, Sinam-myeon, Yesan-gun, Chungcheongnam-do, Korea
340-861 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
31.12.2008 |
|
|
|
|
Date of Incorporation : |
17.03.1971 |
|
|
|
|
Com. Reg. No.: |
109-81-10032 |
|
|
|
|
Legal Form : |
Co., Ltd by shares |
|
|
|
|
Line of Business : |
Manufacture of Animal Medicaments |
|
|
|
|
No. of Employees : |
44 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
Unknown |
|
Litigation : |
Clear |
NOTES
:
Any query related to this report
can be made on e-mail: infodept@mirainform.com while quoting report
number, name and date.
ECGC Country Risk Classification List – June 30th,
2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
South Korea - ECONOMIC OVERVIEW
South Korea over the past four decades has demonstrated incredible
growth and global integration to become a high-tech industrialized economy. In
the 1960s, GDP per capita was comparable with levels in the poorer countries of
Africa and Asia. In 2004, South Korea joined the trillion dollar club of world
economies, and currently is among the world's 20 largest economies. Initially,
a system of close government and business ties, including directed credit and
import restrictions, made this success possible. The government promoted the
import of raw materials and technology at the expense of consumer goods, and
encouraged savings and investment over consumption. The Asian financial crisis
of 1997-98 exposed longstanding weaknesses in South Korea''s development model
including high debt/equity ratios and massive short-term foreign borrowing. GDP
plunged by 6.9% in 1998, and then recovered by 9% in 1999-2000. Korea adopted
numerous economic reforms following the crisis, including greater openness to
foreign investment and imports. Growth moderated to about 4% annually between
2003 and 2007. With the global economic downturn in late 2008, South Korean GDP
growth slowed to 0.3% in 2009. In the third quarter of 2009, the economy began
to recover, in large part due to export growth, low interest rates, and an
expansionary fiscal policy, and growth was 3.6% in 2011. In 2011, the US-South
Korea Free Trade Agreement was ratified by both governments and is projected to
go into effect in early 2012. The South Korean economy''s long term challenges
include a rapidly aging population, inflexible labor market, and heavy reliance
on exports - which comprise half of GDP.
|
Source : CIA |
Basic
|
Company
Name |
SAMU MEDIAN CO., LTD. (Korean Company Name : “(주)삼우메디안”) |
|
Registered Address |
254-15, Dugok-ri, Sinam-myeon, Yesan-gun,
Chungcheongnam-do, Korea |
|
Zip Code |
340-861 |
|
Tel |
+82-41-331-3511 |
|
Fax |
+82-41-331-3514 |
|
E-mail |
samu@samu.co.kr |
|
Website |
www.samu.co.kr;www.vetmed.co.kr;www.companionanimal.co.kr |
|
Trading Address |
632-7, Deungchon 1-dong, Gangseo-gu,
Seoul, Korea |
|
Tel |
+82-2-366-13511~4 |
|
Fax |
+82-2-3661-3690 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Animal Medicaments |
|
Main
Business |
Veterinary Products |
|
Sub
Business |
|
|
Established (mm/dd/yyyy) |
03/17/1971 |
The Subject owns
the premises of registered HQ address.
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Veterinary products(42121600) |
|
Sell |
Veterinary antibiotics(51102600) |
|
Sell |
Veterinary anthelmintics(51102500) |
|
Name |
Lee Wan-Sang |
|
Address |
493-25, Yeonnam-dong, Mapo-gu, Seoul, Korea |
|
Date of Birth |
11/03/1937 |
|
Title |
Chairam & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Mr. Lee Wan-Sang works as a director
of Korea Animal Health Product Association, and has worked as Ex. chairman of
Korea Veterinary Pharma Ind. Co-Op.
|
Capital (KRW) |
600,000,000 |
|||||||||||||||
|
Employees |
44 |
|||||||||||||||
|
Formation |
Co., Ltd by shares |
|||||||||||||||
|
Bank Details |
Shinhan Bank-Deungchon Dong Corporate
Finance Branch SC First Bank of Korea-Deungchon Dong
Branch |
|||||||||||||||
|
Corporate Registered No. |
110111-0112071 |
|||||||||||||||
|
Business Registered No. |
109-81-10032 |
|||||||||||||||
|
Permit & Licenses |
Int’l Trade No.: 608907 |
|||||||||||||||
|
Shareholder Position |
|
|||||||||||||||
|
Company History |
05/1969 Established as SAMU CHEMICAL IND.
CO. 03/17/1971 Incorporated as SAMU CHEMICAL
IND. CO., LTD. 05/06/2003 Changed company name to the
present name 05/06/2003 Increased the authorized shares
to 300,000 shares from 40,000 shares 05/07/2003 Increased capital to 600,000,000
KRW from 150,000,000 KRW |
|||||||||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Sex |
Nationality |
Inauguration Date |
|
Chairman & CEO |
Mr. |
Lee Wan-Sang |
Male |
Korean |
11/12/2000 |
|
President & CEO |
Mr. |
Lee Hern-Seok |
Male |
Korean |
01/26/2012 |
|
Director |
Mr. |
Yoo Si-Hyung |
Male |
Korean |
02/03/2009 |
|
Auditor |
Mr. |
Kim Hong-Soo |
Male |
Korean |
03/02/2001 |
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
|
|
|
|
|
2010 |
|
|
|
|
2009 |
5,308,000,000 |
8,938,000,000 |
95,000,000 |
|
2008 |
5,379,274,683 |
8,883,240,414 |
251,365,004 |
|
2007 |
5,205,123,289 |
9,102,458,294 |
48,933,974 |
|
2006 |
5,442,436,006 |
9,169,191,763 |
556,029,197 |
|
2005 |
5,836,402,025 |
8,784,986,036 |
212,101,718 |
|
2004 |
5,145,943,211 |
8,874,624,588 |
270,017,544 |
The latest &
full financials are not available, and the Subject Company does not have any
obligations to release its financials to the public.
|
Authorized Capital(KRW) |
1,500,000,000 |
|
Paid-Up Capital(KRW) |
600,000,000 |
|
Total Issued Shares |
120,000 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Current
Liabilities |
290,888,016 |
430,131,294 |
589,067,430 |
|
Trade Payables |
89,573,319 |
37,771,052 |
57,129,699 |
|
Account Payables |
46,205,470 |
48,218,127 |
38,027,781 |
|
Advance Receipts |
5,896,280 |
3,471,340 |
5,204,215 |
|
Withholdings |
40,247,210 |
38,126,130 |
23,466,450 |
|
VAT Withhold |
32,243,876 |
25,228,572 |
38,917,856 |
|
Accrued Income Tax |
76,721,861 |
277,316,073 |
426,321,429 |
|
Fixed
Liabilities |
940,703,089 |
853,332,095 |
750,800,202 |
|
Provision for Severance &
Retirement |
940,703,089 |
853,332,095 |
750,800,202 |
|
|
|||
|
Unit : Korean Won |
As of 12/31/2008 |
As of 12/31/2007 |
As of 12/31/2006 |
|
Sales |
5,379,274,683 |
5,205,123,289 |
5,442,436,006 |
|
Cost of Sold Goods |
3,140,248,917 |
2,980,498,240 |
3,185,370,612 |
|
Gross Profit |
2,239,025,766 |
2,224,625,049 |
2,257,065,394 |
|
Selling & Admin. Expenses |
2,028,065,368 |
2,165,280,593 |
1,831,190,218 |
|
Operating Income |
210,960,398 |
59,344,456 |
425,875,176 |
|
Non-Operating Income |
44,613,404 |
50,782,907 |
140,222,631 |
|
Non-Operating Expenses |
1,113,610 |
10,361,681 |
10,068,610 |
|
Income Before Taxes |
254,460,192 |
99,765,682 |
556,029,197 |
|
Income Taxes Expenses |
3,095,188 |
50,831,708 |
- |
|
Net Income |
251,365,004 |
48,933,974 |
556,029,197 |
|
|
|||
|
Unit : Korean Won |
As of 12/31/2008 |
As of 12/31/2007 |
As of 12/31/2006 |
|
Cash Flows from Operating |
125,904,884 |
-92,505,616 |
702,999,453 |
|
-Net Income |
251,365,004 |
48,933,974 |
556,029,197 |
|
-Exp. without Cash Outflow |
268,652,308 |
440,562,726 |
263,249,133 |
|
-Revenue without Cash Inflows |
- |
-2,494,969 |
-93,249,047 |
|
-Changes in Asset/ & Liability |
-394,112,428 |
-579,507,347 |
-23,029,830 |
|
Cash Flows from Investing |
474,225,874 |
52,872,034 |
-792,703,015 |
|
-Cash Inflow from Investing |
500,000,000 |
687,572,726 |
17,135,827 |
|
-Cash Outflows for Investing |
-25,774,126 |
-634,700,692 |
-809,838,842 |
|
Cash Flows from Financing |
-420,000,000 |
-60,000,000 |
-60,000,000 |
|
-Cash Inflows from Financing |
- |
- |
- |
|
-Cash Outflows from Financing |
-420,000,000 |
-60,000,000 |
-60,000,000 |
|
Increase/Decrease in Cash |
180,130,758 |
-99,633,582 |
-149,703,562 |
|
Cash at the Beginning of Year |
459,961,236 |
559,594,818 |
709,298,380 |
|
Cash at the End of Year |
640,091,994 |
459,961,236 |
559,594,818 |
|
Main Products & Services |
Veterinary Medicine, Pet Item Veterinary
medicines 1. Antibiotics, Chemotherapeutics (1) Injectable solutions (including Replacement fluid and Spray) (2) Oral Preparations (3) Ointments 2. Anabolics, Hormons (1) Injectables (2) Oral Products 3. Disinfectants, Insecticides (1) Pulveres (powders) (2) Emulsion (3) Solutions (4) Tablets 4. Medicines for fishes Nutrients for
animals - Minerals, Vitamins, Amino acid 1. Injectables 2. Oral Products Premixes for the
feed industry 1. Premixes (Vitamins, Minerals, Amino
acid, probiotics, enzyme) 2. Medicated Additives 3. Alimentary Products 4. Custom Premixs |
|
Competitors |
WOOSUNG CO., LTD. 33-19, TOYANG-RI, EUNJIN-MYEON, NONSAN-SI,
CHUNGCHEONGNAM-DO, KOREA TEL:+82-41-741-7836~40 FAX:+82-41-742-6205 VIXXOL CORPORATION 220-10, ANYANG 7-DONG, MANAN-GU, ANYANG-SI,
GYEONGGI-DO, KOREA TEL:+82-31-467-6767 FAX:+82-31-468-1502 DA ONE CHEMICAL CO., LTD. 1DA-405, SIHWA INDUSTRIAL COMPLEX, 1252-6,
JEONGWANG-DONG, SIHEUNG-SI, GYEONGGI-DO, KOREA TEL:+82-31-498-0001 FAX:+82-31-498-6595 |
|
Cooperative Enterprise |
-Insured Company DONGBU INSURANCE CO., LTD.(110111-0095285) |
Not Available.
No.
---
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian
Rupees |
|
US Dollar |
1 |
Rs.53.94 |
|
UK Pound |
1 |
Rs.86.24 |
|
Euro |
1 |
Rs.72.20 |
INFORMATION DETAILS
|
Report
Prepared by : |
NLM |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for
credit transaction. It has above average (strong) capability for payment of
interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy.
General unfavourable factors will not cause fatal effect. Satisfactory
capability for payment of interest and principal sums |
Fairly
Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet
normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and
principal sums in default or expected to be in default upon maturity |
Limited
with full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be
exercised |
Credit
not recommended |
|
-- |
NB |
New
Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit
history (10%) Market
trend (10%) Operational
size (10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.